Arbutus Total Stockholder Equity from 2010 to 2024

ABUS Stock  USD 3.76  0.08  2.17%   
Arbutus Biopharma Total Stockholder Equity yearly trend continues to be comparatively stable with very little volatility. Total Stockholder Equity will likely drop to about 93.5 M in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2000-03-31
Previous Quarter
122.5 M
Current Value
106.9 M
Quarterly Volatility
133.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 701.5 K or Selling General Administrative of 12.2 M, as well as many indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0529 or PTB Ratio of 3.72. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
  
Check out the analysis of Arbutus Biopharma Correlation against competitors.

Latest Arbutus Biopharma's Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Arbutus Biopharma Corp over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Arbutus Biopharma's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Pretty Stable
   Total Stockholder Equity   
       Timeline  

Arbutus Total Stockholder Equity Regression Statistics

Arithmetic Mean134,774,483
Geometric Mean86,360,803
Coefficient Of Variation96.81
Mean Deviation84,136,414
Median101,966,000
Standard Deviation130,478,789
Sample Variance17024.7T
Range542.5M
R-Value0.14
Mean Square Error17959.5T
R-Squared0.02
Significance0.61
Slope4,171,473
Total Sum of Squares238346T

Arbutus Total Stockholder Equity History

202493.5 M
2023106 M
2022136.9 M
2021169.4 M
2020102 M
201972.7 M
2018200.2 M

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Stockholder Equity106 M93.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.